NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.04 +1.31 (+3.38 %)
(As of 01/21/2019 12:34 PM ET)
Previous Close$38.73
Today's Range$38.61 - $40.32
52-Week Range$26.95 - $55.00
Volume559,235 shs
Average Volume567,801 shs
Market Capitalization$1.65 billion
P/E Ratio-69.03
Dividend YieldN/A
Beta1.57
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$286.63 million
Cash Flow$0.0614 per share
Book Value$6.89 per share

Profitability

Net Income$-42,610,000.00

Miscellaneous

Employees489
Market Cap$1.65 billion
OptionableOptionable

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) released its quarterly earnings data on Thursday, November, 1st. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.40. The firm earned $83.45 million during the quarter, compared to analyst estimates of $79.87 million. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The business's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.11 earnings per share. View Pacira Pharmaceuticals' Earnings History.

When is Pacira Pharmaceuticals' next earnings date?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Pacira Pharmaceuticals.

What guidance has Pacira Pharmaceuticals issued on next quarter's earnings?

Pacira Pharmaceuticals updated its FY 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325-330 million, compared to the consensus revenue estimate of $326.84 million.

What price target have analysts set for PCRX?

17 brokers have issued 12-month price targets for Pacira Pharmaceuticals' shares. Their predictions range from $41.00 to $90.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $55.1333 in the next year. This suggests a possible upside of 37.7% from the stock's current price. View Analyst Price Targets for Pacira Pharmaceuticals.

What is the consensus analysts' recommendation for Pacira Pharmaceuticals?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pacira's top line mainly comprises contribution from its marketed product Exparel. The company’s efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Exparel's label expansion to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira remains optimistic about its partnership with J&J to market and promote the use of Exparel with respective sales and medical education teams. Pacira’s agreement with China-based Nuance for the development and commercialization of Exparel in China is also an upside. Shares of Pacira have outperformed the industry in 2018. However, the company remains heavily dependent on Exparel for growth, which is concerning." (1/3/2019)
  • 2. Mizuho analysts commented, "We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating." (11/1/2018)
  • 3. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)

Has Pacira Pharmaceuticals been receiving favorable news coverage?

News stories about PCRX stock have been trending positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:
  • Mr. David M. Stack, Chairman & CEO (Age 69)
  • Mr. Charles A. Reinhart III, Chief Financial Officer (Age 58)
  • Dr. Richard Scranton M.D., MPH, Chief Scientific Officer (Age 58)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 40)

Who are Pacira Pharmaceuticals' major shareholders?

Pacira Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.49%), Legacy Capital Partners Inc. (0.12%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Pacira Pharmaceuticals stock include Andreas Wicki, Charles A Reinhart III, David M Stack, Gary W Pace, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Which major investors are selling Pacira Pharmaceuticals stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.

Which major investors are buying Pacira Pharmaceuticals stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Legacy Capital Partners Inc.. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy shares of Pacira Pharmaceuticals?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of PCRX stock can currently be purchased for approximately $40.04.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.65 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.

What is Pacira Pharmaceuticals' official website?

The official website for Pacira Pharmaceuticals is http://www.pacira.com.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  636 (Vote Outperform)
Underperform Votes:  427 (Vote Underperform)
Total Votes:  1,063
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Federal Reserve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel